A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers

A Phase 1, Randomized, Open-label, Parallel-group Study To Evaluate The Pharmacokinetics Of Pf-04856883 (Cvx-096) Following Subcutaneous Administration In Healthy Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01637285

Enrollment

Registered

2012-07-11

Start date

2012-08-31

Completion date

2013-01-31

Last updated

2015-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The purpose of the study is to further evaluate the PK characteristics of PF-04856883.

Interventions

BIOLOGICALPF-04856883

Dose A

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
PF-04856883 Pharmacokinetics including Cmax, Tmax, AUCo-infinity, AUClast, Cl/F, Vz/F and t1/2	4 weeks

Secondary

Measure	Time frame
Number of subjects with AEs reported	4 weeks
Number of subjects with abnormal physical examination findings	4 weeks
Number of subjects with abnormal clinical laboratory results	4 weeks
Number of subjects with abnormal ECGs	4 weeks
Number of subjects with abnormal vital signs	4 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026